Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.42 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.41 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.41 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.41 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
| ▸ | USP2 | O75604 | 1/20 | 0.39 |
| ▸ | HTRA1 | Q92743 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | BTK | Q06187 | 1/20 | 0.37 |
| ▸ | ATM | Q13315 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2273886 | 1.00 | HSD17B10 (0.48) | HSD17B10SMN1; SMN2NR1H2CHRM2CHRM1 | |
| SCHEMBL7531758 | 0.87 | NR1H3 (0.41) | HSD17B10SMN1; SMN2NR1H2CHRM2CHRM1 | |
| SCHEMBL21924897 | 0.84 | NAMPT (0.43) | NR1H2CYP1A2POLBCYP3A4CYP2C19 | |
| SCHEMBL3442335 | 0.84 | HSD17B10 (0.43) | HSD17B10SMN1; SMN2NR1H2CHRM2CHRM1 | |
| SCHEMBL1315955 | 0.84 | HSD17B10 (0.43) | HSD17B10SMN1; SMN2NR1H2CHRM2CHRM1 | |
| SCHEMBL24645252 | 0.84 | HSD17B10 (0.43) | HSD17B10SMN1; SMN2NR1H2CHRM2CHRM1 | |
| SCHEMBL8214873 | 0.84 | HSD17B10 (0.43) | HSD17B10SMN1; SMN2NR1H2CHRM2CHRM1 | |
| SCHEMBL5200883 | 0.84 | ATM (0.59) | HSD17B10SMN1; SMN2NR1H2CHRM2CHRM1 | |
| SCHEMBL17033098 | 0.84 | HSD17B10 (0.43) | HSD17B10SMN1; SMN2NR1H2CHRM2CHRM1 | |
| SCHEMBL116439 | 0.84 | ATM (0.59) | HSD17B10SMN1; SMN2NR1H2CHRM2CHRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230357199-A1 | ARYL, HETEROARYL, AND HETEROCYCLIC PHARMACEUTICAL COMPOUNDS FOR TREATMENT OF MEDICAL DISORDERS | ACHILLION PHARMACEUTICALS, INC. | 2023-11-09 | — | — | US | disclosed |
| US-11708351-B2 | Aryl, heteroaryl, and heterocyclic pharmaceutical compounds for treatment of medical disorders | ACHILLION PHARMACEUTICALS, INC. (US) | 2023-07-25 | — | — | US | disclosed |
| US-11649229-B2 | Amide compounds for treatment of immune and inflammatory disorders | ACHILLION PHARMACEUTICALS, INC. (US) | 2023-05-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11649229-B2 | Amide compounds for treatment of immune and inflammatory disorders | CFD, TFPI, CFH | HSD17B10 2518/4885SMN1; SMN2 4650/4885NR1H2 914/4885 |
| US-11708351-B2 | Aryl, heteroaryl, and heterocyclic pharmaceutical compounds for treatment of medical disorders | CFD, TFPI, CFH | HSD17B10 1063/4885SMN1; SMN2 3485/4885NR1H2 519/4885 |
| US-20230357199-A1 | ARYL, HETEROARYL, AND HETEROCYCLIC PHARMACEUTICAL COMPOUNDS FOR TREATMENT OF MEDICAL DISORDERS | CFD, TFPI, CFH | HSD17B10 1063/4885SMN1; SMN2 3485/4885NR1H2 519/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.